Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AYTU BIOPHARMA, INC

Get SEC filing alerts via email and in your feed for AYTU BIOPHARMA, INC

AYTU

AYTU BIOPHARMA, INC

About AYTU BIOPHARMA, INC

Aytu BioPharma, Inc. is a pharmaceutical company specializing in innovative treatments for central nervous system disorders, primarily major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Its core products include EXXUA, a novel selective serotonin 5HT1a receptor agonist for MDD, and extended-release orally disintegrating tablets Adzenys and Cotempla for ADHD. The company also offers pediatric allergy and fluoride supplement products, marketing primarily in the U.S. through third-party wholesalers and an internal sales force.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from AYTU BIOPHARMA, INC

1
1
AYTU BIOPHARMA, INC Aytu BioPharma Reports 33% Revenue Decline and $5.6 Million Net Loss for Q3 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
AYTU BIOPHARMA, INC Aytu BioPharma Reports Decline in Revenue and Net Loss for Q2 Fiscal 2026

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
AYTU BIOPHARMA, INC Aytu BioPharma Reports $13.9 Million Revenue, Enters Exclusive Agreement for EXXUA

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
AYTU BIOPHARMA, INC Aytu BioPharma Reports $13.6 Million Net Loss and $66.4 Million Revenue for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 8 months ago | 0 comments

5
1
AYTU BIOPHARMA, INC Aytu BioPharma Reports 32% Revenue Growth to $18.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
AYTU BIOPHARMA, INC Aytu BioPharma Reports 13% Revenue Decline in Q2 Fiscal 2025, Focuses on ADHD Products

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
AYTU BIOPHARMA, INC Aytu BioPharma Reports 7% Revenue Decline, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments